Summit Therapeutics plc

10/07/2019 | Press release | Distributed by Public on 10/07/2019 05:12

Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile[...]